Market Overview

JP Morgan Initiates Intersect ENT With Overweight


Analysts at JP Morgan initiated coverage on shares of Intersect ENT (NASDAQ: XENT) with a Overweight rating.

The target price for Intersect ENT is set to $22.

Intersect ENT's shares surged 1.33% to $15.25 in pre-market trading.

Latest Ratings for XENT

Nov 2020BTIGUpgradesNeutralBuy
Nov 2020SVB LeerinkMaintainsMarket Perform
Oct 2020JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for XENT
View the Latest Analyst Ratings


Related Articles (XENT)

View Comments and Join the Discussion!

Posted-In: JP MorganInitiation Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at